Sodium 4-(((3-((4-cyanonaphthalen-1-yl)(methyl)amino)pyridin-4-yl)thio)methyl)-3-methoxybenzoate

ID: ALA5190525

Chembl Id: CHEMBL5190525

PubChem CID: 168281558

Max Phase: Preclinical

Molecular Formula: C26H20N3NaO3S

Molecular Weight: 455.54

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1cc(C(=O)[O-])ccc1CSc1ccncc1N(C)c1ccc(C#N)c2ccccc12.[Na+]

Standard InChI:  InChI=1S/C26H21N3O3S.Na/c1-29(22-10-9-18(14-27)20-5-3-4-6-21(20)22)23-15-28-12-11-25(23)33-16-19-8-7-17(26(30)31)13-24(19)32-2;/h3-13,15H,16H2,1-2H3,(H,30,31);/q;+1/p-1

Standard InChI Key:  GNXUKKVJHAQDQR-UHFFFAOYSA-M

Associated Targets(Human)

SLC22A6 Tclin Solute carrier family 22 member 6 (265 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC22A12 Tclin Solute carrier family 22 member 12 (799 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC2A9 Tbio Solute carrier family 2, facilitated glucose transporter member 9 (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ABCG2 Tchem ATP-binding cassette sub-family G member 2 (4927 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 455.54Molecular Weight (Monoisotopic): 455.1304AlogP: 5.87#Rotatable Bonds: 7
Polar Surface Area: 86.45Molecular Species: ACIDHBA: 6HBD: 1
#RO5 Violations: 1HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.82CX Basic pKa: 5.35CX LogP: 3.82CX LogD: 2.05
Aromatic Rings: 4Heavy Atoms: 33QED Weighted: 0.35Np Likeness Score: -1.00

References

1. Zhao Z, Liu J, Kuang P, Luo J, Surineni G, Cen X, Wu T, Cao Y, Zhou P, Pang J, Zhang Q, Chen J..  (2022)  Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.,  229  [PMID:34998055] [10.1016/j.ejmech.2021.114092]

Source